Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Symbotic Inc (SYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Symbotic Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.97 (market cap $29.60B), while Symbotic Inc trades at $41.48 (market cap $5.41B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 5.5× Symbotic Inc's market cap. Which is the better fit depends on your goals.
| ALNY | SYM | |
|---|---|---|
Market Cap | $29.60B | $5.41B |
Sector | Health | Technology |
52-Week High | $491.22 | $87.30 |
52-Week Low | $205.48 | $38.57 |
Enterprise Value | $27.56B | $3.67B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
SYM trades at $41.17, up 2.64% today but facing bearish technical signals with 15 sell indicators. The company reported mixed Q3 2026 results with revenue growth of 21.7% but an earnings miss. Despite negative net income of -$16.94M in 2025, cash flow remains strong at $516.84M and analysts maintain a $60 consensus target with 61% buy ratings.
SYM presents a growth story with expanding revenue and margin improvements, but faces execution risks amid recent earnings misses. The stock offers potential upside to analyst targets but requires careful monitoring of profitability trends and competitive pressures in the warehouse automation sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Symbotic Inc
Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →
